Advertisement · 728 × 90
#
Hashtag
#Sugemalimab
Advertisement · 728 × 90
Preview
CStone Pharmaceuticals Reveals Strategic Growth and Innovation Amid 2025 Annual Results Release Discover how CStone Pharmaceuticals plans to accelerate its global presence and enhance its innovative pipeline with the latest annual results for 2025.

CStone Pharmaceuticals Reveals Strategic Growth and Innovation Amid 2025 Annual Results Release #China #Suzhou #CStone_Pharmaceuticals #CS2009 #Sugemalimab

1 0 0 0
Preview
CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC CStone Pharmaceuticals has received new indication approval from the UK MHRA for sugemalimab, aimed at patients with Stage III non-small cell lung cancer, expanding its global reach.

CStone Secures Historic MHRA Approval for Sugemalimab Treatment in Stage III NSCLC #United_Kingdom #N/A #NSCLC #CStone #Sugemalimab

0 0 0 0
Preview
Sugemalimab Plus Chemotherapy vs Chemotherapy in Gastric Cancer: Cost-Effectiveness Insights from China - OncoDaily Sugemalimab plus chemotherapy improves survival in gastric cancer but is not yet cost-effective in China, highlighting price and policy challenges.

Sugemalimab Plus Chemotherapy vs Chemotherapy in Gastric Cancer: Cost-Effectiveness Insights from China

oncodaily.com/trial-update...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Sugemalimab #Chemotherapy #GastricCancer #China

3 0 0 0
Preview
CStone Pharmaceuticals Reports 2024 Results and Strategic Developments in Oncology CStone Pharmaceuticals has unveiled robust 2024 annual results, highlighting significant revenue growth and strategic advancements in cancer therapies.

CStone Pharmaceuticals Reports 2024 Results and Strategic Developments in Oncology #China #Suzhou #CStone_Pharmaceuticals #Sugemalimab #avapritinib

0 0 0 0
Preview
CStone Pharmaceuticals Advances Sugemalimab Application for Stage III Non-Small Cell Lung Cancer to EMA CStone Pharmaceuticals has submitted a Type II variation application for sugemalimab, targeting stage III non-small cell lung cancer, to the EMA, enhancing its oncology portfolio.

CStone Pharmaceuticals Advances Sugemalimab Application for Stage III Non-Small Cell Lung Cancer to EMA #China #Suzhou #CStone_Pharmaceuticals #Sugemalimab #Non-Small_Cell_Lung_Cancer

0 0 0 0
Preview
PD-L1-Inhibitor zur First-Line-Therapie von fortgeschrittenem Magenkrebs Für Menschen mit therapienaivem inoperablem fortgeschrittenem Adenokarzinom des Magens oder des ösophagogastralen Übergangs zeichnet sich eine weitere Therapieoption ab: der PD-L1-Hemmer Sugemalimab.

Mit #Sugemalimab wurde jetzt erstmals ein PD-L1-Inhibitor zur Erstlinientherapie von inoperablen lokal fortgeschrittenen oder metastasierten Adenokarzinomen des Magens und des ösophagogastralen Übergangs in einer Phase-3-Studie getestet – mit Erfolg: #Medizin #MedSky #Magenkarzinom

0 1 0 0
Preview
CStone Pharmaceuticals' Sugemalimab Study Breaks Ground in Gastric Cancer Treatment with New JAMA Publication CStone Pharmaceuticals has announced groundbreaking results from the GEMSTONE-303 study, showcasing sugemalimab's efficacy as a first-line treatment for gastric cancer, now published in JAMA.

CStone Pharmaceuticals' Sugemalimab Study Breaks Ground in Gastric Cancer Treatment with New JAMA Publication #China #Suzhou #CStone #Sugemalimab #JAMA

0 0 0 0
Preview
CStone Pharmaceuticals Celebrates New ESMO Guideline Inclusion for Sugemalimab Treatment in NSCLC CStone Pharmaceuticals announces its leading cancer therapy, Sugemalimab, is now part of ESMO's guidelines for NSCLC, marking a significant milestone.

CStone Pharmaceuticals Celebrates New ESMO Guideline Inclusion for Sugemalimab Treatment in NSCLC #China #Suzhou #NSCLC #CStone #Sugemalimab

0 0 0 0
Preview
CStone Pharmaceuticals Enters Strategic Partnership with SteinCares for Sugemalimab in Latin America CStone partners with SteinCares for the commercialization of Sugemalimab across 10 Latin American countries. This deal marks a significant milestone for both companies in expanding access to innovative cancer therapies.

CStone Pharmaceuticals Enters Strategic Partnership with SteinCares for Sugemalimab in Latin America #China #Suzhou #SteinCares #CStone #Sugemalimab

0 0 0 0